Does any of this replace your treatment?
No. The prescribed plan is the base. Food, weight, drink, movement, sleep and stress sit beside it, and they are worth having on their own terms. Evidence Evidence Evidence
Why this matters
- Reasonably supported
The National Institute of Arthritis and Musculoskeletal and Skin Diseases sets out the broad map of psoriasis care. It covers treatment you put on the skin, light treatment, oral systemic medicine and biologics. NICE assessment reads several things together. It reads skin, nails, high-impact sites, daily life and joint concerns. So daily life already sits inside the clinical picture rather than outside it. The National Psoriasis Foundation is blunt about the line. Supplements should never replace medication. It asks you to talk with your health care provider before you change how you eat.
Considerations
- Depends on you
None of these records scores a daily habit against a plaque. They do not rank one habit against another, and they do not set a plan for one reader. NICE is UK guidance, so it fixes no US treatment order. A change that improves your general health is worth making for that reason alone. That is a different claim from clearing skin.
Questions for your dermatologist
Which parts of my routine are worth keeping even if they do not treat psoriasis?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would you want me to work on first, alongside the treatment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What do weight, food and drink actually change?
Less than a headline promises, and more than nothing. The registered guidance here is general, and it says so plainly. Evidence Evidence
Why this matters
- Reasonably supported
The National Psoriasis Foundation states that no diet cures psoriatic disease. It states that eating patterns may lessen symptom severity for some people. It supports gradual weight loss for people who are overweight. The American Academy of Dermatology records that limiting alcohol is linked to treatment working better and lasting longer. It also links limiting alcohol to a lower risk of liver damage from some psoriasis medicines. On tobacco, it records that quitting is linked to fewer flares and to more remissions. It cautions that a nicotine patch can make psoriasis flare, so ask a dermatologist before using one.
Considerations
- Depends on you
Neither body gives an effect size for one person, and neither gives a timeline. Neither sets a target weight for a reader, and neither ranks one named diet over another. Diet and psoriasis carries the food detail. Alcohol and smoking carries the drink and tobacco thresholds, which is where a number belongs.
Questions for your dermatologist
Is weight worth working on alongside my treatment, or after it settles?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Does what I drink change the medicine I am on?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Where do movement and sleep fit?
Both are general health first. Sleep also carries a psoriasis-specific record, because itch is what takes the nights away. Evidence Evidence
Why this matters
- Reasonably supported
The Centers for Disease Control and Prevention lists general sleep habits. A steady sleep and wake schedule. A cool, quiet bedroom. Screens off before bed. No large meal, alcohol or caffeine close to bedtime. Regular exercise sits on that same list. A 2023 study measured sleep in 200 people with psoriasis. Poor sleep quality ran at 16 per cent overall. It was 11.8 per cent in mild psoriasis, 25 per cent in moderate and 50 per cent in severe. People with worse itching scored worse on every sleep measure checked.
Considerations
- Depends on you
The CDC list is written for everyone, and it does not claim to treat a skin condition. A diagnosed sleep disorder needs its own clinician. The 2023 study ran at one hospital in Egypt, with no comparison group and a questionnaire rather than a sleep lab. It shows a pattern across a group, not a cause. Nothing in these records measures exercise against plaque severity. Sleep and stress carries the rest of that ground.
Questions for your dermatologist
Is my sleep bad enough to treat in its own right?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Is there a kind of exercise you would avoid with my joints?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does stress run both ways?
It is recorded in both directions. Stress is a reported flare trigger, and living with psoriasis is itself hard on mood. Evidence Evidence Evidence Evidence Evidence
Why this matters
- Reasonably supported
The American Academy of Dermatology lists stress among reported psoriasis triggers. It records that triggers differ from person to person. One study used a UK family-doctor database. It tracked more than 145,000 people with psoriasis and a much larger group without it. It found higher rates of noted depression, noted anxiety and noted self-harm risk. The rise in depression showed up even in mild psoriasis. A separate study screened skin-clinic patients in 13 European countries. Low mood was about twice as common there as in people with no skin problem. The joint AAD and NPF guideline asks clinicians to screen people with psoriasis for depression.
Considerations
- Depends on you
None of this shows that psoriasis causes low mood. The UK study counts only what a doctor wrote down, so it misses what nobody raised. The European study does not split psoriasis out from the other skin conditions. Asking for help is not a detour from skin treatment. The National Institute of Mental Health supports professional help when mental health concerns interfere with life. It points to the US 988 Lifeline or emergency services when there are thoughts of self-harm.
Questions for your dermatologist
Can we talk about mood at the same visit as my skin?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who would you refer me to if I wanted that kind of support?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
How do you judge a supplement or a natural product?
By what a registered record establishes, which is usually the caution rather than a result. Then by what else you already take. Evidence Evidence Evidence
Why this matters
- Reasonably supported
The National Psoriasis Foundation reports that omega-3 supplement research is mixed and needs more long-term controlled studies. It reports that vitamin D research in psoriasis is small and limited, and that too much vitamin D can be dangerous. It reports that no study has found glucosamine or chondroitin reduce psoriatic arthritis symptoms. It states that supplements should never replace medication. The National Center for Complementary and Integrative Health adds that supplement evidence varies. So does what is actually in the bottle. Interactions, contamination and health-condition risks are all possible.
Considerations
- Depends on you
Natural, traditional and clinically tested say nothing about the quality of the evidence behind a product. The interaction question is the sharp one if you take a systemic medicine. AAD and NPF guidance names methotrexate, apremilast, cyclosporine and acitretin among established systemic nonbiologic options. SteadySkin sets no amount, no strength and no schedule for a product named here. Complementary approaches covers the product-by-product picture.
Questions for your dermatologist
I am taking ___. Could it interact with my psoriasis medicine?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Would you like to see the label before I start ___?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
How do you raise this at your next appointment?
As a record, not a confession. One list of what you take and use, plus what you changed since the last visit. Evidence Evidence
Why this matters
- Reasonably supported
The National Psoriasis Foundation asks you to bring a symptom tracker to your appointment. Paper or a phone both count, and it is meant to be shared. It asks you to describe symptoms clearly. It asks you to note changes in severity and in the areas affected. NICE assessment covers skin, nails, high-impact sites, daily life and joint concerns. So the daily part of this belongs in the room.
Considerations
- Depends on you
The foundation page gives no percentage and no timeline for what tracking changes. It does not say what a supplement record should hold. NICE is UK guidance, and it judges no urgency from a description. Changing two things at once is what makes the answer unreadable later.
Questions for your dermatologist
Here is everything I take and put on my skin. Does any of it clash with my plan?
Saving keeps this on your device and needs JavaScript, which is off in this browser.How long should we give this before we look at it together?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- National Institute of Mental HealthPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports seeking professional help when mental-health concerns interfere with life and using the U.S.
What it does not support
988 Lifeline or emergency services when there are thoughts of self-harm or immediate danger. The source gives only a 2025 revision year; it does not diagnose a condition, assess an individual’s safety or provide crisis services outside the United States.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Centers for Disease Control and PreventionGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: US federal public-health agency; general population guidance, no product or manufacturer tie.
What this source supports
Supports general sleep-hygiene habits for the general population. A consistent sleep and wake schedule, in a cool and quiet bedroom. Turning off electronic devices at least 30 minutes before bed. Avoiding large meals, alcohol and caffeine close to bedtime. Regular exercise.
What it does not support
Is not specific to vitiligo, does not claim these habits treat any skin condition, and does not address a diagnosed sleep disorder, which needs a clinician.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that stress can trigger a psoriasis flare. Supports that skin injury - a cut, scrape, sunburn, tattoo, piercing, bug bite, or shaving nick - can trigger a flare near or at that spot. Typically this appears about 10 to 14 days after the injury. Supports that an infection such as strep throat, an earache, or bronchitis can trigger a flare, reported 2 to 6 weeks later. Supports that starting a medication - including lithium, antimalarial drugs, strong corticosteroids, or some blood pressure drugs - can trigger a flare about 2 to 3 weeks after starting it. Supports that cold, dry weather (such as winter or fall) can worsen flares, and that sunburn or spending time in air conditioning can also worsen them. Supports that smoking, or spending time around secondhand smoke, is a reported trigger. Supports that drinking daily, or more than two drinks on several days a week, can make psoriasis treatment have little or no effect. Supports that triggers differ from person to person.
What it does not support
Does not cite a specific study for its trigger list or timing windows, and does not state how many patients experience each trigger. This page displays no revision date; the date recorded here matches the same AAD psoriasis disease microsite's treatment-and-diagnosis page, checked the same day. Does not establish that avoiding a listed trigger will prevent a flare for any one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Scientific Reports (Zaky MS, Elgamal EA, Mohamed DH, Abd Al Maksoud AA, Elsaie ML)Observational study · Clinical research, tier 2Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Government research-funding acknowledgment only (Egypt STDF/EKB); the authors state no competing interests.
What this source supports
Supports that in a study of 200 people with psoriasis, 16% had poor sleep quality overall. That rose to 50% among people with severe psoriasis and 25% with moderate psoriasis, against 11.8% with mild psoriasis. Supports that people with worse itching had much worse sleep on every measure checked. Supports that higher disease-severity scores lined up with worse sleep quality, shorter sleep, and more sleep disturbance. Both links were strong enough that chance alone is an unlikely explanation.
What it does not support
A single-hospital study in Egypt. It had no comparison group and mostly mild-to-moderate cases. Sleep was measured with a questionnaire, not a sleep lab. It shows a pattern across a group, not that itching causes poor sleep. It does not predict any one person’s sleep.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Archives of Dermatology (Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict notes were not checked beyond the published record. So the status here is set to not established.
What this source supports
Supports that one study used a UK family-doctor database. It tracked more than 145,000 people with psoriasis. It also tracked a much larger group with no psoriasis. Supports a higher rate of noted depression in the psoriasis group. Supports a higher rate of noted anxiety. Supports a higher rate of noted self-harm risk. Supports that the rise in depression showed up in mild psoriasis. Supports that the rise was larger in severe psoriasis.
What it does not support
Does not show that psoriasis causes any of this. Does not judge or predict one person. It counts only what a doctor wrote down. So it misses what was never raised in a visit. It covers one database and one span of years. It does not describe US care today.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of Investigative Dermatology (Dalgard FJ, Gieler U, Tomas-Aragones L)Observational study · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict notes were not checked beyond the published record. So the status here is set to not established.
What this source supports
Supports that skin-clinic patients in 13 European countries were screened. They were screened for low mood, for worry, and for thoughts of self-harm. A group with no skin problem was screened too. Supports that low mood was about twice as common in the patient group. Supports that worry was more common in the patient group. Supports that thoughts of self-harm were more common there too. Supports that psoriasis was one of the skin problems in the study.
What it does not support
Does not split psoriasis out from the other skin problems. Does not give a figure for psoriasis alone. It looked at people at one point in time. So it cannot show what came first. Does not judge or predict one person. It was run in Europe and does not describe US care today.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that no diet cures psoriatic disease, and that eating patterns may lessen symptom severity for some people. Supports a Mediterranean-style pattern: cold-water fish at least twice a week, plus fruits, vegetables, whole grains, low-fat dairy, and lean meat and poultry without skin. Supports limiting alcohol, sodium, trans and saturated fats, and refined sugar and processed food. The alcohol limit is one drink a day for women and two for men, or none for severe psoriasis. The sodium limit is under 1,500 mg a day. Supports that a gluten-free diet is recommended only for confirmed gluten sensitivity or celiac disease. Supports gradual weight loss, about 1 to 2 pounds a week, for people who are overweight. Supports using the CDC BMI calculator to find a target weight, as one part of managing the disease. Supports that omega-3 supplement research is mixed and needs more long-term controlled studies. Supports that vitamin D research is small and limited, and that too much vitamin D can be dangerous. Supports that no study has found glucosamine or chondroitin reduce psoriatic arthritis symptoms. Supports that supplements should never replace medication, and that you should talk with your health care provider before starting any diet change.
What it does not support
Does not give an effect size for how much any food pattern, weight change, or supplement changes symptoms for a given person. Does not recommend a single named diet over another beyond referencing Mediterranean-style eating. Does not substitute for a treatment plan.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that quitting smoking is linked to fewer flares and less palmoplantar psoriasis. Supports that it is linked to more remissions. Supports that quitting also lowers the risk of heart, blood vessel, liver, and gum disease. Supports that it lowers the risk of an autoimmune disease like Crohn's disease. Supports the caution that a nicotine patch can make psoriasis flare, and to ask a dermatologist before using one. Supports that limiting alcohol is linked to treatment working better and lasting longer. Supports that it is linked to a lower risk of psoriatic arthritis in women. Supports that it is linked to a lower risk of fatty liver disease and liver damage from some psoriasis medications. Supports a named threshold: more than 2 drinks a day for men, or more than 1 for women. Supports that above that threshold, treatment may stop working, work less well, or lead to fewer remissions.
What it does not support
Does not give a percentage or timeline for one person. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the American Academy of Dermatology (Elmets CA, Leonardi CL, Davis DMR, et al.)Guideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships with industry. It is expert guidance, not independent proof for one person.
What this source supports
Supports that this guideline covers psoriasis alongside other health conditions. Supports naming psoriatic arthritis as one of them. Supports naming heart and blood vessel disease. Supports naming obesity, high blood pressure, raised blood fats and diabetes. Supports naming inflammatory bowel disease. Supports naming uveitis, an inflammation inside the eye. Supports naming depression and anxiety. Supports that it asks clinicians to screen people with psoriasis for psoriatic arthritis. Supports that it asks them to check heart risk factors. Supports naming body weight, blood pressure, blood fats and blood sugar among those checks. Supports that it asks them to screen for depression.
What it does not support
Does not diagnose a reader. Does not say which linked condition one person will get. Does not read a test result or set a personal plan. Its authors report industry relationships. It is US guidance. It does not set practice in another country.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing a symptom tracker, kept on paper or on a phone, to share with a doctor at an appointment. Supports clearly describing symptoms and noting changes in severity and affected areas as part of preparing for a visit.
What it does not support
Does not mention photographing skin changes specifically. The page shows no visible byline or update date. The site copyright year, 2026, is used here.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Center for Complementary and Integrative HealthPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports general US consumer context that supplement evidence and product content vary and that interactions, contamination and health-condition risks are possible.
What it does not support
It is not vitiligo-specific efficacy evidence, a product-quality verification service or an individual safety determination.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships; it is not independent comparative proof for an individual choice.
What this source supports
Supports that methotrexate, apremilast, cyclosporine and acitretin are established systemic nonbiologic options considered in psoriasis care.
What it does not support
It does not select, rank or prescribe an option for an individual reader.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a broad patient-facing map of topical treatment, phototherapy, oral systemic treatment and biologic treatment. Also supports that a doctor usually diagnoses psoriasis by examining the skin, scalp and nails, and by asking about itchy or burning skin, medications, family history, recent illness or severe stress, and joint tenderness. Also supports that a doctor may take a small skin sample to examine under a microscope to rule out other skin conditions that look like psoriasis.
What it does not support
It does not rank categories or choose treatment for a particular person. It does not list a blood test as part of diagnosing psoriasis itself, and it does not diagnose psoriatic arthritis.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.